NZ Minimum Quality Standard (MQS) for Cannabis 2026

Every cannabis product supplied in New Zealand must clear the Minimum Quality Standard. The MQS is the single release gate between a finished batch and the NZ market.

The Minimum Quality Standard (MQS) is the verification regime set out in Part 1 of the Misuse of Drugs (Medicinal Cannabis) Regulations 2019. It is administered by the Medicinal Cannabis Agency (MCA) inside the Ministry of Health, and it covers eight specific tests that every batch of medicinal cannabis must pass before it can be supplied in New Zealand. This page lays out the full NZ Minimum Quality Standard cannabis test list, the European Pharmacopoeia anchors, the assay limits for dried flower versus pharmaceutical dosage forms, the split between GMP-certified and ISO 17025 accredited labs, and what happens when a batch fails verification.

For the wider regulatory picture, our NZ medicinal cannabis compliance checklist covers licensing, GACP, GMP, security, and export amendments alongside this MQS deep dive.

What Is the Minimum Quality Standard (MQS) for NZ Medicinal Cannabis?

The MQS is the legal verification standard that every medicinal cannabis product must meet before it is supplied in New Zealand. It is set out in Part 1 of the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 and administered by the Medicinal Cannabis Agency (MCA), the unit inside the Ministry of Health responsible for the Medicinal Cannabis Scheme.

Three things make the MQS distinctive in the global cannabis regulatory landscape:

• It is a pre-supply gate, not an annual audit. A batch that has not been MQS-verified cannot be supplied to a pharmacy, prescriber, or patient. Verification happens lot by lot.
• It anchors most tests to the European Pharmacopoeia. Rather than write bespoke NZ test methods, the regulations point at the European Pharmacopoeia for microbial, heavy metals, pesticides, mycotoxins, and residual solvents. This is the same pharmacopoeial framework used by the European Medicines Agency and most EU-aligned medicinal cannabis programmes.
• It requires accredited laboratory work. Six of the eight tests must be run by a GMP-certified laboratory. The remaining two accept ISO 17025 accreditation. There is no in-house testing pathway for MQS verification.

The MQS sits alongside the Medsafe-issued Licence to Manufacture and the GACP cultivation requirements. A batch that meets GACP at the field stage and GMP at the manufacturing stage still cannot be supplied if it fails MQS at the verification stage. The three frameworks are independent gates, not substitutes.

For supply chain context, see our spokes on NZ medicinal cannabis licence requirements, NZ cannabis GACP cultivation requirements, and NZ cannabis GMP Medsafe requirements.

What Tests Does the NZ Minimum Quality Standard Cannabis Programme Require?

The NZ Minimum Quality Standard cannabis test schedule covers eight categories, taken verbatim from the Misuse of Drugs (Medicinal Cannabis) Regulations 2019 and the MCA product specification. Every batch supplied in New Zealand must clear every applicable line in this table.

A few practical notes on the table.

• Heavy metals quartet. The four regulated metals are arsenic, cadmium, lead, and mercury. Cannabis is a known hyperaccumulator, so the per-batch screen catches uptake from soil, irrigation water, and amendments. Limits follow the European Pharmacopoeia elemental impurities chapter.
• Mycotoxins are split out. Aflatoxins and Ochratoxin A get their own line, which is consistent with European Pharmacopoeia general monographs on herbal drugs.
• Residual solvents only matter if they were used. If the manufacturing process used Class 1, 2, or 3 solvents, the lab tests against the European Pharmacopoeia residual solvents chapter. Solvent-free cultivars and water-extract products still need a documented justification on the batch record.
• Stability studies are an ICH-style commitment. Shelf life data must be generated under defined storage conditions, with a documented stability protocol, and the assigned shelf life on the label must be supported by the data.

Which Tests Require GMP-Certified Labs vs ISO 17025 Labs?

The NZ Minimum Quality Standard cannabis programme splits the eight tests across two laboratory accreditation tiers. Picking the wrong tier on the wrong test is a documentation failure even when the numerical result passes, so QAPs need to keep the split clear in the supplier file.

Six of the eight MQS tests sit in the GMP-certified tier. That is the operationally significant point. A supplier file built around an ISO 17025 lab alone is not enough to verify a NZ batch. The cannabis-experienced GMP labs that serve the NZ market are a relatively short list, and lead times often run weeks rather than days, so QAPs should plan release timing around the GMP lab calendar, not against a generic ISO 17025 turnaround.

Two scope-annex audit habits worth building into the QAP routine:

• Verify the cannabis matrix is on the GMP scope. A GMP certificate that covers tablet manufacturing tells you nothing about cannabis flower potency assay. The certificate scope annex must list the specific matrix (dried flower, oil, tincture, capsule) and the specific method (HPLC, GC-MS, LC-MS, ICP-MS) the lab is accredited for.
• Verify the European Pharmacopoeia method version. Pharmacopoeial chapters get revised. The lab should be running the current edition method, and the COA should cite the chapter and revision used.

What Are the NZ MQS Assay Limits for Cannabis Products?

The active ingredient assay test in the NZ Minimum Quality Standard cannabis schedule sets two distinct numerical limits, depending on the product format. These are the most operationally significant numbers in the MQS and the ones most likely to drive a release failure.

Three implications for the manufacturing and release teams:

• Label accuracy is enforced numerically, not aspirationally. A lot that measures 12 percent THC against a 16 percent label claim sits at 75 percent of stated content and fails the dried product band. Relabelling is not allowed as a workaround unless the entire batch documentation is reissued.
• Pharmaceutical dosage forms need tighter content uniformity controls. The 90 to 110 percent band for oils and capsules is tighter than the 80 to 120 percent band for dried flower because pharmaceutical manufacturing is expected to deliver consistent content per dose. Validated mixing, fill weight checks, and content uniformity testing on representative samples per batch are the operational answer.
• Failing MQS means the lot cannot be supplied in New Zealand. The regulations are clear: a product that does not meet the MQS cannot be supplied to a pharmacy, prescriber, or patient in NZ. The lot is either reworked (where permitted), quarantined pending decision, or destroyed under the destruction SOPs documented in the GACP file.

How Does the NZ MQS Compare to European Pharmacopoeia Standards?

The NZ MQS is, in effect, a NZ-specific reference into the European Pharmacopoeia (Ph. Eur.). Six of the eight MQS test categories cite European Pharmacopoeia standards directly, which means a NZ-supplied batch is being verified against the same chapters used by EU-aligned medicinal cannabis programmes.

This pharmacopoeial alignment is one of the structural strengths of the NZ scheme for export-minded operators. A batch built to pass the NZ MQS has, by construction, cleared the European Pharmacopoeia test framework on five of the six pharmacopoeial categories. That is meaningful overlap with the EMA-aligned medicinal cannabis frameworks in Germany, Australia (under the TGA), and the United Kingdom.

One operational caveat: alignment on the test framework is not the same as alignment on the legal release authority. A NZ MQS-verified batch is not automatically importable into Germany or Australia. Each destination jurisdiction has its own import licence, GMP equivalence rules, and labelling requirements. The pharmacopoeial overlap reduces test rework, but it does not collapse three regulatory files into one.

What Happens If a Batch Fails MQS Verification?

A batch that fails any MQS test cannot be supplied in New Zealand. The regulatory consequence is unambiguous, but the operational response runs through a structured deviation and CAPA workflow that should already exist in the QMS as part of the Medsafe GMP commitment.

1. Quarantine. The failed lot goes into both system and physical quarantine within 24 hours of the failing COA. Sister lots from the same harvest, same manufacturing run, or same input batch should also be flagged for review pending root cause.
2. Deviation report. File the deviation with the failing test, the measured value, the applicable MQS limit, the lot identifier, and the lab COA reference. Link to the batch record and the input material certificates.
3. Root cause investigation. The investigation depth depends on the failing test. A heavy metals failure runs through grow media, irrigation water, fertilisers, and substrate suppliers. A microbial failure runs through environmental monitoring data, harvest handling, drying conditions, and packaging. An assay failure runs through the manufacturing process record and the analytical method.
4. Sideways sweep. If the root cause traces to a supplier input or a process step that touched other lots, those sister lots are reassessed. This is especially important for cannabis given that input material drift (a fertiliser change, a new water source) often affects multiple batches before being detected.
5. CAPA. Document the corrective action (immediate fix) and preventive action (programme change) in the QMS. Update SOPs, supplier specifications, and incoming material testing as appropriate.
6. Disposition. The lot is reworked (where regulatorily permitted and technically feasible), held for additional testing under documented rationale, or destroyed. Destruction follows the destruction SOPs documented in the GACP cultivation file. See the NZ cannabis GACP cultivation requirements spoke for the destruction SOP framework.
7. MCA notification considerations. The MQS regulations do not impose an automatic notification requirement on a single failed batch in the way that a security incident requires Police notification (immediate) and MCA notification (within 3 days). However, a recurring failure pattern, a recall trigger, or a deviation that affects already-supplied product changes the picture. The QAP should escalate any of these to MCA proactively.

The export pathway is a partial relief valve here. Under the July 2024 export amendments, NZ exports only need to meet the importing jurisdiction’s quality standards, not the NZ MQS. A batch that fails NZ MQS but meets a less strict destination standard (for example, certain industrial CBD wellness markets) may still be exportable under a controlled drug export licence, provided the destination’s importer holds the appropriate import licence. This is an option to consider during disposition, not a default workflow.

Frequently Asked Questions

Who administers the NZ Minimum Quality Standard for cannabis?

The Medicinal Cannabis Agency (MCA), a unit inside the New Zealand Ministry of Health. The MCA is responsible for the Medicinal Cannabis Scheme established under the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, including MQS verification, the five licence activity types, and the published list of MQS-verified products on the Ministry of Health website.

Can a NZ medicinal cannabis batch be tested in-house?

No. Six of the eight MQS tests must be run by a GMP-certified laboratory with the cannabis matrix and analytical method on the GMP scope. The remaining two tests (foreign matter and ash content; shelf life and storage conditions) accept ISO 17025 accreditation. There is no in-house testing pathway for MQS verification, even for licensed manufacturers with their own quality control labs.

What is the NZ MQS assay band for dried cannabis flower?

80 to 120 percent of stated content. A dried flower lot labelled at 20 percent THC must measure between 16 and 24 percent on the validated potency assay. Pharmaceutical dosage forms (oils, capsules, oromucosal sprays) get the tighter 90 to 110 percent band because the manufacturing process is expected to deliver consistent content per dose.

Does a NZ MQS-verified batch automatically meet European Pharmacopoeia standards?

For five of the six pharmacopoeial categories, yes by construction. The NZ MQS cites the European Pharmacopoeia directly for microbiological contamination, heavy metals, pesticide residues, aflatoxins and Ochratoxin A, and residual solvents. Pharmacopoeial alignment on test method does not equal regulatory equivalence on import authority. Each destination jurisdiction has its own import licence, GMP equivalence rules, and labelling framework that must be cleared independently.

Get the Complete NZ Compliance Checklist

The full PDF puts the MQS verification table next to the licensing pathway, GACP cultivation requirements, Medsafe GMP submission, security obligations, and the July 2024 export amendments. Built for QAPs preparing a NZ batch release file or planning a Medicinal Cannabis Scheme application.

Download Free Guide